Literature DB >> 3276575

Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits.

K Kono1, K Ohnishi, M Omata, M Saito, T Nakayama, H Hatano, Y Nakajima, S Sugita, K Okuda.   

Abstract

An attempt was made to develop an animal model for the study of the etiology of noncirrhotic portal fibrosis or idiopathic portal hypertension based on the assumption that it is related to chronic abdominal infection. Rabbits were given killed nonpathogenic Escherichia coli intraportally or intravenously. The animals to which a mixture of killed E. coli and rabbit antiserum (aggregated E. coli) was given intraportally developed remarkable histologic changes in the liver. The early inflammatory reactions in the portal area and parenchyma were followed by rapid disappearance of inflammation and development of portal fibrosis with bile duct proliferation. Three intraportal challenges with aggregated E. coli were sufficient to produce pronounced portal fibrosis, although there was considerable variation in response among individual animals. This procedure also produced splenomegaly, and in some animals marked portal hypertension. Injection of nonaggregated killed E. coli into the portal vein or aggregated E. coli into the ear vein also caused similar hepatic changes, but they were milder in degree. These histologic changes resemble portal fibrosis seen in idiopathic portal hypertension and, less closely, pericholangitis associated with inflammatory bowel disease in humans.

Entities:  

Mesh:

Year:  1988        PMID: 3276575     DOI: 10.1016/0016-5085(88)90255-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Non-cirrhotic portal fibrosis.

Authors:  S K Sarin
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

Review 3.  A systematic review of diagnostic tests for small intestinal bacterial overgrowth.

Authors:  Reza Khoshini; Sun-Chuan Dai; Sheila Lezcano; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

Review 4.  Clinical characteristics of idiopathic portal hypertension.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

5.  Extraintestinal manifestations of granulomatous enterocolitis induced in rabbits by long-term submucosal administration of muramyl dipeptide emulsified with Freund's incomplete adjuvant.

Authors:  K Kuroe; Y Haga; O Funakoshi; I Mizuki; K Kanazawa; Y Yoshida
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

Review 6.  Noncirrhotic portal hypertension.

Authors:  Harshal Rajekar; Rakesh K Vasishta; Yogesh K Chawla; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 7.  The current clinical aspects of idiopathic portal hypertension.

Authors:  Tomohiro Tanaka; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

8.  Does endothelium agree with the concept of idiopathic hepatic vessel thrombosis?

Authors:  Ozgur Harmanci; Yahya Buyukasik; Serafettin Kirazli; Ferhun Balkanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

Review 9.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

10.  Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension.

Authors:  Kadim Bayan; Yekta Tüzün; Serif Yilmaz; Naime Canoruc; Mehmet Dursun
Journal:  J Thromb Thrombolysis       Date:  2008-08-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.